Considerations for Earlier Use of Radiopharmaceutical Therapy in Prostate Cancer.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 41991401.
- Also identified by DOI 10.1016/j.eururo.2026.03.002.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Local and androgen-deprivation therapies are guideline recommendations in localized and metastatic prostate cancer, respectively. However, in select patients the alternative use of radiopharmaceutical therapies may be considered to delay or avoid quality-of-life decline associated with other systemic treatments.